“If the technology is so great, then at least one of those projects would have been funded to its successful completion by now,” says analyst Jonathan Aschoff, affirming his Sell rating on Inovio (NASDAQ:INO) and $11 price target.
The company’s COVID-19 vaccine candidate INO-4800 “has virtually no chance” of winning out among the numerous competitors, he adds.
He’s also no fan of Inovio’s VGX-3100, saying it’s “destined to be a commercial failure.”
Inovio soared 36% yesterday, and is up about 75% for the week after company CEO Joseph Kim presented at a healthcare conference. Presentation slides are here.
https://seekingalpha.com/news/3614965-inovio-bear-roth-capital-unimpressed-stocks-big-move-this-week
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.